Restasis, expiring in its patent on the 17th, has shaken up the xerophthalmia market

Restasis(cyclosporine, Allergan Korea), which is well known as the first xerophthalmia treatment in the world, has shaken up the market as it will be expired in its patent on the 17^th of this month.

Domestic companies, waiting for the expiration after acquiring generic approvals in advance, seem to come forward in sales on the 18^th.

According to the pharmaceutical industry on the 13^th, its ge...